back to homepage


Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications, Amends GLP-1 Agreement

Emisphere to Receive $14 Million Upfront for New License and Amendment, Eligible for More Than $207 Million in Milestone Payments, Plus Royalties on Product Sales ROSELAND, N.J., Oct. 15, 2015

Read More

Featured Jobs: FDA JobWatch

December 2015: Now Posted on FDA JobWatch — Novo Nordisk jobs in clinical research, clinical data analysis, clinical project management and more! Novo Nordisk – Tampa, FL Regional Clinical Research

Read More

Report: G-Protein Coupled Receptors (GPCR)

G-Protein Coupled Receptors (GPCR) report provides insight on G-Protein Coupled Receptors (GPCR) and covers the types of GPCR Families and the various ligands targeting GPCR. The GPCR families covered include Rhodopsin, Secretin,

Read More

FDA Gives Nod Of Approval To Roche Hemophilia Drug

Roche announced Friday that ACE910 has been recognized as a breakthrough therapy by the U.S. Food and Drug Administration for treating those aged at least 12 years old diagnosed with

Read More